(NASDAQ: ALVO) Alvotech's forecast annual revenue growth rate of 27.44% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.27%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.38%.
Alvotech's revenue in 2025 is $587,890,000.On average, 2 Wall Street analysts forecast ALVO's revenue for 2025 to be $196,669,254,972, with the lowest ALVO revenue forecast at $191,646,604,895, and the highest ALVO revenue forecast at $201,692,206,854. On average, 2 Wall Street analysts forecast ALVO's revenue for 2026 to be $257,715,187,453, with the lowest ALVO revenue forecast at $230,806,495,097, and the highest ALVO revenue forecast at $284,623,879,808.
In 2027, ALVO is forecast to generate $386,616,090,294 in revenue, with the lowest revenue forecast at $386,616,090,294 and the highest revenue forecast at $386,616,090,294.